Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 18/20 | 0.89 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.89 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.89 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-2636771 SCHEMBL29352801 | 0.94 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| Gsk-2636771 SCHEMBL1280998 | 0.94 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| Gsk-2636771 SCHEMBL29411881 | 0.94 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| Gsk-2636771 SCHEMBL16323314 | 0.93 | PIK3C2B (0.98) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| Gsk-2636771 SCHEMBL1281470 | 0.89 | PIK3C2B (0.89) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1282217 | 0.88 | PIK3C2B (0.80) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL14922445 | 0.88 | PIK3C2B (0.80) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1282244 | 0.87 | PIK3C2B (0.83) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1280975 | 0.87 | PIK3C2B (0.87) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1633027 | 0.87 | PIK3C2B (0.87) | PIK3C2BPIK3CBPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER CENTER (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | CXCR3, MTOR, CX3CR1 | PIK3C2B 96/4885PIK3CB 276/4885PIK3CD 360/4885 |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | BMP4, P2RY2, GPR39 | PIK3C2B 1199/4885PIK3CB 1673/4885PIK3CD 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.